PFE Jul 2024 17.000 call
| Previous close | 12.70 |
| Open | 12.70 |
| Bid | 12.00 |
| Ask | 12.10 |
| Strike | 17.00 |
| Expiry date | 2024-07-19 |
| Day's range | 12.70 - 12.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
ZacksAbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
Associated Press FinanceFDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines
Government advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall -- targeting a version of the ever-evolving coronavirus called JN.1. Moderna, Pfizer and Novavax all have tested doses updated to match the JN.1 variant that became dominant last winter. FDA’s advisers voted Wednesday that the next vaccine should come from the JN.1 “lineage” or family.
GlobeNewswireRelay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NY
